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In a recent issue of *Critical Care*, Parnell and colleagues examined host gene expression changes in whole blood from critically ill patients infected with pandemic H1N1 influenza A infection \[[@B1]\]. The measurable genomic response of the host to influenza may provide important information not only on viral pathogenesis but also on the immune response, its dissemination within the infected host, and its transmission in a population. The authors evaluated transcriptional changes in blood samples obtained from 39 patients and 18 healthy controls. Of the 39 patients, eight had polymerase chain reaction (PCR)-confirmed pandemic H1N1 influenza A virus, 16 had culture-documented bacterial pneumonia, and 12 had systemic inflammatory response syndrome of undefined etiology. The investigators also enrolled three patients with apparent influenza and bacterial co-infection. A support vector machine class predictor identified a blood-based H1N1 gene expression signature, but a separate unique bacterial signature, or secondary bacterial infection, could not be generated.

Distinguishing bacterial pneumonia from other causes of upper and lower respiratory tract infection, particularly influenza, is challenging. Improvements in the timely and accurate classification of the causative agent(s) of respiratory infection could have a profound impact on health and quality of life by improving appropriate antibiotic use and infection control interventions. The development of inexpensive and easy-to-use rapid diagnostics to accurately distinguish bacterial pneumonia from viral pneumonia in routine clinical specimens (for example, blood) would represent a major advance in health care and have a significant impact on improving the clinical management and outcome of acute pneumonias.

At present, infectious disease diagnostics focus on one or more pathogens of interest (for example, the urinary pneumococcal antigen test or multiplex PCR for respiratory viruses) or one-analyte-at-a-time biomarkers (for example, C-reactive protein or procalcitonin elevation as a marker for severe bacterial infections \[[@B2],[@B3]\]). However, the sensitivity and specificity of these approaches have been limited. In other fields, high-dimensional gene expression data offer a higher level of precision in the diagnosis of acute and chronic diseases \[[@B4],[@B5]\]. Infectious disease lends itself well to these analyses since the host response to pathogens entails a cascade of cellular events and expressed molecules that can be readily measured on a genome scale. The dimension and complexity of such data provide unique opportunities to uncover patterns that can distinguish subtle phenotypes in ways that traditional single-molecule techniques cannot and to use these patterns in models to predict with precision the way the genome interacts with environmental stimuli, such as infectious or other noxious agents.

Recently, strategies have been developed by several groups to use host gene expression to classify viral \[[@B6],[@B7]\], bacterial \[[@B8]\], and fungal \[[@B9]\] bloodstream infections - a strategy termed a \'paradigm shift\' by some investigators in the field \[[@B10]\]. The rationale for this approach is clear - immune effector cells respond to pathogens with characteristic gene expression patterns reflecting the interaction of the pathogen with pattern recognition receptor signaling. These patterns, captured by microarray or alternative technologies, offer robust classification of infectious pathogens. *In vitro*\[[@B11]-[@B13]\] and *ex vivo*\[[@B14]\] data provide proof-of-concept that gene expression patterns exhibited by host immune cells have, in addition to common cellular programs, pathogen-specific components.

Parnell and colleagues should be applauded for their work in this area and extending the paradigm of hostbased classification of infectious disease. However, the study has some limitations that need to be recognized so that future investigations of this type continue to move this important area of investigation forward. The sample size is relatively small and thus the generalizability of the findings remains to be elucidated. The authors recognize that additional validations with expanded cohorts are necessary to determine whether these findings represent an H1N1-specific molecular signature or one that is more representative of influenza viruses or other respiratory pathogens \[[@B6]\]. In addition, the question of whether these results would be generalizable to population extremes (such as the very young or the aged and immune-compromised) and the impact of medications, particularly antiviral and other antimicrobial drugs, on the accuracy of the classifier would absolutely need to be addressed. Array-based analysis has limited utility for clinical infectious disease diagnostics, and the signatures developed here need to be migrated to a more conventional platform for diagnostics, such as reverse transcription-PCR, and revalidated. Critical work on sample processing, turnaround time, and sensitivity, specificity, and negative and positive predictive values also would need to be assessed prior to any claims about the suitability of the signatures as a diagnostic. It is interesting that the investigators were unable to develop a signature for the bacterial pneumonia where others have had some success \[[@B8],[@B15]\]. Perhaps this reflects the heterogeneity of the subjects, issues with accurate phenotyping, or statistical methodology limitations. Bacterial pneumonias are heterogeneous, and the details of the case definition and adjudication of the phenotypes in these types of studies are critical components of the study design. The development of a specific bacterial host response signature will be essential to the advancement of this technology to clinical application. Nonetheless, the results of this work are a significant step forward in the use of genomics to understanding the host response to an important pathogen in global health.
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